top of page

MULti-Tumour based prediction and manipulation of Immune Response

Multir in numbers
Multir project #eu research

Launched in January 2024, MULTIR will be running for four years until 2028. The project is coordinated by the National Institute of Health and Medical Research (INSERM) in France. The consortium encompasses a total of 17 partners, comprising 15 beneficiaries and 2 associated partners. Additionally, MULTIR is integrated into the Cancer Mission cluster of projects focused on “Understanding tumor-host interactions”.

Scope #mission cancer

The overarching goal of MULTIR is to enhance survival rates through personalized treatment, achieved by predicting optimal therapeutic approaches based on host-tumor interaction models and facilitating targeted manipulation of these interactions to improve therapy response. Aligned with the Cancer Mission objectives set forth by the EU, the identified associations between tumors and hosts, along with a systematic comprehension of molecular and host-related factors affecting therapy response, will inform the development of AI-based tools (apps). These tools, created in collaboration with patients, guideline committee members, and regulators, will undergo testing in vivo, in vitro, and ex vivo, followed by assessment in clinical trials. By advancing personalized treatments, these tools aim to promote more strategic therapy utilization, mitigating potential toxic effects and socioeconomic burdens.

Latest news


MULTIR kick-off meeting

We are thrilled to announce the successful launch of the MULTIR consortium, which convened in the beautiful city of Paris on January 24th and 25th, 2024. This inaugural meeting was held in a hybrid format, blending in-person and virtual participation to maximize engagement. Hosted by our coordinator, Inserm, the event united all consortium partners for dynamic discussions and collaborative strategizing.
  • Instagram
  • LinkedIn
bottom of page